TCM
STRO icon

Tang Capital Management’s Sutro Biopharma STRO Stock Holding History

Tang Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-139,617
Closed -$1.62M – 71
2025
Q4 		$1.62M Sell
139,617
-143,255
-51% -$1.36M 0.08% 67
2025
Q3 		$2.46M Buy
282,872
+26,713
+10% +$227K 0.09% 117
2025
Q2 		$1.83M Buy
256,159
+236,159
+1,181% +$1.93M 0.09% 123
2025
Q1 		$130K Buy
+20,000
New +$315K 0.01% 201

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Tang Capital Management's STRO Position: Q1 2026 in Review

Tang Capital Management sold out of Sutro Biopharma (STRO) in Q1 2026, closing a stake of 139,617 shares — an estimated $1.62M sold.

Tang Capital Management first reported a position in STRO in Q1 2025 and held it in 4 quarters. The position peaked at $2.46M in Q3 2025. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Tang Capital Management reported no remaining Sutro Biopharma position as of Q1 2026 after selling out during the quarter.
  • Tang Capital Management sold 139,617 Sutro Biopharma shares in Q1 2026, an estimated $1.62M.
  • Tang Capital Management first reported a position in Sutro Biopharma in Q1 2025 and held it in 4 quarters.
  • Tang Capital Management's Sutro Biopharma position peaked at $2.46M in Q3 2025.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Tang Capital Management's 13F filing for Q1 2026, filed 15 May 2026.